Working to support research and guide clinical practice is the main goal of The Biomarkers Consortium. This collaborative effort ensures that the voice of all stakeholders involved in biomarker research is heard and contributes to strides made in support of promising initiatives undertaken by The Consortium in areas such as cancer, inflammation and immunity, metabolic disorders and neuroscience.
For Profit Partners
The Biomarkers Consortium was established by the Foundation for the National Institutes of Health, the National Institutes of Health, the U.S. Food and Drug Administration and Pharmaceutical Research and Manufacturers of America. In addition, the Centers for Medicare & Medicaid Services and Biotechnology Industry Organization have been instrumental in the implementation and organization of The Biomarkers Consortium.
Join the Biomarkers Consortium
The Biomarkers Consortium embraces government, industry, patient advocacy groups and not-for-profit organizations, each of which has a stake in the identification, development and the seeking of regulatory approval for biomarkers. As a group, we are addressing one of the most pressing needs in the diagnosis and treatment of disease: the development and the seeking of regulatory approval for disease biomarkers and surrogates.
All public- and private-sector partners are involved in consortium governance and contribute their scientific and technical expertise as advisors to the effort. In addition, public partners – NIH, FDA, CMS and other federal agencies – may contribute financial resources and manage the conduct of projects under The Biomarkers Consortium. Members pay annual dues to participate in this unique collaborative effort and receive cross-sector interaction.
Become part of the public-private partnership that is prioritizing biomarkers of most critical need. Founding members include the FNIH (our managing organization), National Institutes of Health, the U.S. Food and Drug Administration and the Pharmaceutical Research and Manufacturers of America.